Effect of neoadjuvant vs. adjuvant systemic therapy on survival in patients with surgical resected limited stage small-cell lung cancer: a real-world retrospective cohort study from SEER database
In the real world, neoadjuvant systemic therapy was associated with improved survival in surgical resected SCLC, especially for those with stage III disease. This indicates that neoadjuvant therapy might be a promising treatment modality for resectable locally advanced SCLC.
Authors
- Fan Yang (ORCID: https://orcid.org/0000-0001-5718-9420)
- Geyun Chang (ORCID: https://orcid.org/0000-0002-9882-6278)
- Changtai Zhao (ORCID: https://orcid.org/0000-0001-8630-9188)
- Yan Ju (ORCID: https://orcid.org/0000-0002-2807-4824)
- Xiao Li (ORCID: https://orcid.org/0000-0003-1992-3529)
- Jingwei Zhang (ORCID: https://orcid.org/0000-0002-0855-7327)
- Yan Xiang (ORCID: https://orcid.org/0000-0002-8027-5615)
- Ruoyi Jin
- Zewen Sun (ORCID: https://orcid.org/0000-0002-7830-5491)
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-09-01
- DOI
- https://doi.org/10.21037/tlcr-2025-457
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00